Shares in US biotech company Exact Sciences have soared nearly 90% this year. But fund manager Dani Saurymper said the run may not be over yet. The Nasdaq-listed company conducts colon cancer testing. Earlier this week, the company said its next-generation screening test, Cologuard 2.0, showed a 30% reduction in false positive rates for detecting the disease in a study compared with approved tests. The positive results from the study, called BLUE-C, come at an important time for the company. Saurymper, who manages Pacific Asset Management’s Longevity and Social Change Fund, said the absence of millions of screenings during the Covid-19 pandemic has created a huge demand for Exact Sciences’ testing technology. “It’s a huge opportunity. A company like Exact is clearly jumping at it,” Saurymper said Wednesday on CNBC’s Pro Talks. EXAS 1Y line Saurymper’s funds focus on finding investment opportunities in companies at higher risk of aging populations, which Saurymper refers to as “longevity industries”. Their screening methodology involves examining companies’ revenue streams and ranking them based on how much revenue those industries generate. Companies with more than half of their revenue from these industries are considered high-risk exposures. One of the themes that Saurymper highlighted to investors was disease prevention and screening. He argues that it is more beneficial to focus on companies that encourage healthy living and prevent disease than companies that focus on providing cures. That’s where Exact Sciences comes in. The company was losing money at one point, but screening volumes have ramped up significantly and it expects to turn a profit this year. Last year, the company’s screening business brought in $1.4 billion in revenue, most of it from sales of an FDA-approved colon cancer test. Analysts also welcomed the new study’s findings. “Overall, we see compelling (and relatively solid) top-line performance for BLUE-C from Exact’s next-generation Cologuard,” Canaccord Genuity analyst Kyle Mikson said in a note. Give the stock a buy rating. Revealed to customers on June 20. In addition, Exact Sciences is also developing a “liquid biopsy” that aims to use blood tests to detect early signs of liver cancer, which can be expanded to detect other forms of liver cancer in the future. While investors have welcomed the gains this year, shares of Exact have suffered along with other tech sector stocks over the past two years. Saurymper believes the stock has adjusted and has plenty of room to grow going forward. “Its fundamentals have caught up with the stock price,” he told CNBC’s Arabile Gumede. “We certainly think it has significant growth ahead and we’re not going to back down just yet.”